Proprietary AI analyst is now available
- Public Comps
- InventisBio
InventisBio Valuation Multiples
Discover revenue and EBITDA valuation multiples for InventisBio and similar public comparables like Alembic Pharmaceuticals, AnaptysBio, Hualan Biological Vaccine, Yantai Dongcheng and more.
InventisBio Overview
About InventisBio
InventisBio Co Ltd is an innovative drug research and development enterprise based in China with a global perspective, focusing on major diseases such as tumors and metabolic diseases. It has independently developed a series of innovative targeted drugs with patent protection, covering non-small cell lung cancer, breast cancer, colorectal cancer and other solid tumors, as well as hyperuricemia and metabolic diseases such as gout.
Founded
2013
HQ

Employees
N/A
Website
Financials (LTM)
EV
$1B
Valuation Multiples
Start free trialInventisBio Financials
InventisBio reported last 12-month revenue of $11M and negative EBITDA of ($44M).
In the same LTM period, InventisBio generated $10M in gross profit, ($44M) in EBITDA losses, and had net loss of ($42M).
Revenue (LTM)
InventisBio P&L
In the most recent fiscal year, InventisBio reported revenue of $6M and EBITDA of ($44M).
InventisBio is unprofitable as of last fiscal year, with gross margin of 87%, EBITDA margin of (808%), and net margin of (832%).
Financial data powered by Morningstar, Inc.
InventisBio Stock Performance
InventisBio has current market cap of $2B, and enterprise value of $1B.
Market Cap Evolution
InventisBio's stock price is $2.61.
InventisBio share price decreased by 9.1% in the last 30 days, and by 45.1% in the last year.
InventisBio has an EPS (earnings per share) of $-0.08.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $2B | -0.2% | -9.1% | -6.3% | -45.1% | $-0.08 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialInventisBio Valuation Multiples
InventisBio trades at 120.5x EV/Revenue multiple, and (29.6x) EV/EBITDA.
EV / Revenue (LTM)
InventisBio Financial Valuation Multiples
As of June 5, 2026, InventisBio has market cap of $2B and EV of $1B.
InventisBio has a P/E ratio of (36.4x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified InventisBio Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


InventisBio Margins & Growth Rates
InventisBio grew revenue by 232% but EBITDA decreased by 8% in the last fiscal year.
In the most recent fiscal year, InventisBio reported gross margin of 87%, EBITDA margin of (808%), and net margin of (832%).
InventisBio Margins
InventisBio Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
InventisBio Operational KPIs
InventisBio's Rule of 40 is 7% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
InventisBio's Rule of X is 355% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
InventisBio Competitors
InventisBio competitors include Alembic Pharmaceuticals, AnaptysBio, Hualan Biological Vaccine, Yantai Dongcheng, ArriVent BioPharma, Vir Biotechnology, MBX Biosciences, Ab&B Bio-Tech, SOTHEMA and Bora Pharmaceuticals.
Most InventisBio public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 2.4x | 2.1x | 14.7x | 13.6x | |||
| 5.2x | 6.6x | 17.8x | 18.9x | |||
| 6.8x | 6.4x | 24.5x | 26.0x | |||
| 3.7x | 3.6x | 17.2x | 16.3x | |||
| - | - | (6.8x) | (6.7x) | |||
| 16.9x | 10.7x | (2.6x) | (2.9x) | |||
| - | - | (10.6x) | (8.8x) | |||
| 41.5x | - | (59.3x) | - | |||
This data is available for Pro users. Sign up to see all InventisBio competitors and their valuation data. Start Free Trial | ||||||
InventisBio VC Funding History
Before going public, InventisBio raised $247M in total equity funding, across 4 rounds.
InventisBio Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout InventisBio
| When was InventisBio founded? | InventisBio was founded in 2013. |
| Where is InventisBio headquartered? | InventisBio is headquartered in China. |
| Is InventisBio publicly listed? | Yes, InventisBio is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of InventisBio? | InventisBio trades under 688382 ticker. |
| When did InventisBio go public? | InventisBio went public in 2022. |
| Who are competitors of InventisBio? | InventisBio main competitors include Alembic Pharmaceuticals, AnaptysBio, Hualan Biological Vaccine, Yantai Dongcheng, ArriVent BioPharma, Vir Biotechnology, MBX Biosciences, Ab&B Bio-Tech, SOTHEMA, Bora Pharmaceuticals. |
| What is the current market cap of InventisBio? | InventisBio's current market cap is $2B. |
| What is the current revenue of InventisBio? | InventisBio's last 12 months revenue is $11M. |
| What is the current revenue growth of InventisBio? | InventisBio revenue growth (NTM/LTM) is 221%. |
| What is the current EV/Revenue multiple of InventisBio? | Current revenue multiple of InventisBio is 120.5x. |
| Is InventisBio profitable? | No, InventisBio is not profitable. |
| What is the current EBITDA of InventisBio? | InventisBio has negative EBITDA and is not profitable. |
| What is InventisBio's EBITDA margin? | InventisBio's last 12 months EBITDA margin is (408%). |
| What is the current EV/EBITDA multiple of InventisBio? | Current EBITDA multiple of InventisBio is (29.6x). |
| How many companies InventisBio has acquired to date? | InventisBio hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies InventisBio has invested to date? | InventisBio hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to InventisBio
Lists including InventisBio
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.